Literature DB >> 8476233

Antibiotic therapy for chronic infection of pseudomonas in the lung.

N Høiby1.   

Abstract

Chronic Pseudomonas aeruginosa lung infection is an endobronchiolitis characterized by the microcolony mode of growth (biofilm). Early colonization is treated with oral ciprofloxacin combined with colistin inhalation. Chronic infection is treated with "maintenance chemotherapy" consisting of beta-lactam antibiotics and tobramycin intravenously in combination with colistin inhalation four times yearly.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8476233     DOI： 10.1146/annurev.me.44.020193.000245

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  25 in total

1.  Surface plasmon resonance shows that type IV pili are important in surface attachment by Pseudomonas aeruginosa.

Authors:  A Toby A Jenkins; Angus Buckling; Marsha McGhee; Richard H ffrench-Constant
Journal:  J R Soc Interface       Date:  2005-06-22       Impact factor: 4.118

2.  Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.

Authors:  Stephanie J Wallace; Jian Li; Craig R Rayner; Kingsley Coulthard; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

3.  A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Daniel E Fenker; Cameron T McDaniel; Warunya Panmanee; Ralph J Panos; Eric J Sorscher; Carleen Sabusap; John P Clancy; Daniel J Hassett
Journal:  Int J Respir Pulm Med       Date:  2018-11-29

4.  Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.

Authors:  Cornelia B Landersdorfer; Tri-Hung Nguyen; Linh Thuy Lieu; Gary Nguyen; Robert J Bischof; Els N Meeusen; Jian Li; Roger L Nation; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 5.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

6.  Expression of the psl operon in Pseudomonas aeruginosa PAO1 biofilms: PslA performs an essential function in biofilm formation.

Authors:  Jörg Overhage; Mirle Schemionek; Jeremy S Webb; Bernd H A Rehm
Journal:  Appl Environ Microbiol       Date:  2005-08       Impact factor: 4.792

7.  Comparison of arbitrarily primed PCR and macrorestriction (pulsed-field gel electrophoresis) typing of Pseudomonas aeruginosa strains from cystic fibrosis patients.

Authors:  D Kersulyte; M J Struelens; A Deplano; D E Berg
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

8.  Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice.

Authors:  Wan C Tsai; Marc B Hershenson; Ying Zhou; Umadevi Sajjan
Journal:  Inflamm Res       Date:  2009-03-07       Impact factor: 4.575

Review 9.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

10.  Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; S B Duffull; M Kinzig-Schippers; U Holzgrabe; U Stephan; G L Drusano; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.